Archive - 2016

Abstracts

Pre-Clinical Evaluation of the PI3K-p110ß/δ Inhibitor KA2237 in Mantle Cell Lymphoma.
Huang S., Nastoupil L.J., Guo H., Bell T., Ahmed M., Li C.J., Wang J., Liu Y.,  Zhang V., Kim C.R., Boyle J.N., Lorence E.A., Lam L.T., Chen Z., Zhang H., Shuttleworth S.J., Nomie K., Wang M., Zhang L.
Abstract 1837. 58th ASH Annual Meeting and Exposition, San Diego, CA, December 3-6 2016.

Events

2-6 December 2016
ASH Annual Meeting, San Diego, California, USA

Events

1 December 2016
Genesis, London, UK 

Events

28 November - 1 December 2016
EORTC Meeting, Munich, Germany 

Events

15-16 November 2016
FT Global Pharmaceutical & Biotechnology Conference, London, UK

Events

7-9 November 2016
BioEurope, Cologne, Germany

Events

7-9 November 2016
NCRI, Liverpool, UK 

04 November 2016 - In the News

Karus Therapeutics features in BioCentury Innovations

Karus Therapeutics, a leader in the design and development of innovative cancer therapeutics, was featured in BioCentury Innovations, ‘One Plus One Equals Four’. 

Read more

21 October 2016 - Press Releases

Karus Therapeutics presenting at BIO-Europe

Oxford, UK, 21 October 2016 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its CEO will be delivering a presentation at the 22nd BIO-Europe, Cologne, Germany, 7-9 November 2016.

Read more

Events

18-19 October 2016
BIO Investor Forum, San Francisco, USA

Events

17-18 October 2016
Peakdale Drug Discovery & Development Symposium, Liverpool, UK 

Events

13 October 2016
SMR Rare Disease Conference, London, UK 

Events

7-11 October 2016
ESMO 2016 Congress, Copenhagen, Denmark

05 October 2016 - Press Releases

Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center

Oxford, UK, 5 October 2016 – Karus Therapeutics (‘Karus’), a leader in the development of innovative, orally-active medicines with breakthrough potential in the treatment of cancer, today announced that the first patients have been dosed in a Phase I study for its lead candidate, KA2237. 

Read more

03 October 2016 - Press Releases

Karus Therapeutics giving lecture at BIO Investor

Oxford, UK, 3 October 2016 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its CEO will be delivering a lecture at the 15th Annual BIO Investor Forum, San Francisco, California, USA, 18-19 October 2016.

Read more

Events

24-28 September 2016
AACR Cancer Immunotherapy Conference, New York, USA

Events

19-22 September 2016
DoT Kinase Conference, Boston, USA
(Stephen Shuttleworth presenting)

Events

7-9 September 2016
EORTC Meeting, Brussels, Belgium 

07 September 2016 - Press Releases

Karus Therapeutics giving lecture at 10th Annual Symposium – Next Generation Histone Deacetylase Inhibitors

Oxford, UK, 7 September 2016 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced its CSO will be attending and delivering a lecture at the 9th Annual Kinase Inhibitor Discovery conference, Boston, USA, 19 September 2016.

Read more

01 September 2016 - Press Releases

Karus Therapeutics delivering lecture at 9th Annual Kinase Inhibitor Discovery conference

Oxford, UK, 1 September 2016 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced its CSO will be attending and giving a lecture at the 9th Annual Kinase Inhibitor Discovery conference, Boston, USA, 21-22 September 2016.

Read more

Publications

Inhibition of histone deacetylase 6 reveals a potent immunosuppressant effect in models of transplantation.
Ellis J, Neil D, Inston N, Jenkinson E, Drayson M, Hampson P, Shuttleworth S, Ready A, Cobbold M.
Transplantation 2016, 100(8), 1667

Events

17-20 June 2016
13th International Conference on Malignant Lymphoma, Lugano, Italy

Events

6-9 June 2016
BIO International Convention, San Francisco, USA

Events

3-7 June 2016
ASCO 2016, Chicago, USA

Abstracts

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity.
Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finnemore D., Gatland A., Haque K., Lensun L., Roitt S., Rogers H., Silva F.A., Ward P., Whale A., Shuttleworth S.J.
Abstract 207. 14th CIMT Annual Meeting, Mainz, Germany, May 10-12, 2016.